Mvasi FDA Approval History
FDA Approved: Yes (First approved September 14, 2017)
Brand name: Mvasi
Generic name: bevacizumab-awwb
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Non-Small Cell Lung Cancer, Colorectal Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Mvasi (bevacizumab-awwb) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Development timeline for Mvasi
| Date | Article |
|---|---|
| Sep 14, 2017 | Approval FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin |
| Nov 15, 2016 | Amgen and Allergan Submit Biosimilar BLA for ABP 215 to U.S. FDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
